Number of the records: 1
Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"
Title Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE" / Sufliarsky J. Another responsib. Šufliarsky, Jozef (Bibliographic antecedent) Redakcia Onkológia (Adapter) Translated title Aktivita a bezpečnosť krizotinibu u pacientov s pokročilým svetlobunkovým sarkómom s MET alteráciami. Európska organizácia pre výskum a liečbu rakoviny, štúdia fázy 2 90101 "CREATE" Note Ann Oncol, 2017, Sep 18 In Onkológia. -- ISSN 1336-8176. -- Roč. 12, č. 5 (2017), s. 379 Call number C 3069 MeSH Subject sarkóm svetlobunkový - genetika - farmakoterapia proteíntyrozínkinázy - antagonisty a inhibítory proteíny protoonkogénové c-met proteín EWS viažuci sa na RNA - genetika prežívanie bez choroby Keywords krizotinib Form, Genre abstrakt v angličtine Language English Country Slovakia Database ARTICLES 
article
Number of the records: 1